Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.

Deiana, S, et al. (2008) Methylthioninium chloride versus rivastigmine and their co-administration efficacy in reversing scopolamine-induced cognitive deficits in a pharmacological mouse model of Alzheimer's disease. Alzheimers Dement 4:T499.

Harrington, C, et al. (2008) Methylthioninium chloride (MTC) acts as a Tau aggregation inhibitor (TAI) in a cellular model and reverses Tau pathology in transgenic mouse models of Alzheimer's disease. Alzheimers Dement 4:T120-T121.

Luna-Muñoz, J, et al. (2008) Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints. Available at Acta Neuropathologica

Melis, V, et al. (2008) Reversal of spatial problem-solving cognitive deficit in a transgenic mouse line overexpressing the repeat domain of Tau by treatment with the Tau aggregation inhibitor methylthioninium chloride. Available at Alzheimer's & Dementia 4:T485.

Murray, A.D. et al. (2008) Tau Aggregation Inhibitor (TAI) therapy with remberTM changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimer's disease (AD). Available at Alzheimer's & Dementia 4:T786.